Enhanced Melphalan Formulations with Integrated Technologies for Personalized Cancer Treatment

The present inventive concept integrates the patented stable melphalan formulations with cutting-edge technologies such as AI, IoT, blockchain, and novel biomaterials to create a more effective and personalized system for cancer treatment.

The original patent provided stable ready-to-use injectable formulations of melphalan. However, the limitations of the original patent lie in its inability to optimize treatment outcomes, monitor degradation, and ensure supply chain integrity. The present inventive concept addresses these limitations by incorporating advanced technologies to enhance the overall system.

The inventive concept comprises a melphalan formulation with enhanced stability against degradation, an AI-based dosing algorithm for optimizing treatment outcomes based on patient-specific data, IoT-enabled sensors for real-time monitoring and controlling of degradation, a blockchain-based supply chain management system for tracking and verifying the authenticity of melphalan formulations, a nanocarrier-based delivery system for melphalan, and a smart packaging system comprising a novel biomaterial that monitors and responds to environmental factors affecting the stability of the drug.

The new claims introduce the synergistic combination of melphalan formulations with AI, IoT, blockchain, and novel biomaterials, which provides a non-obvious and novel solution for personalized cancer treatment, supply chain management, and real-time monitoring of degradation.

Alternative embodiments of the inventive concept could include the use of different AI algorithms, various IoT sensor configurations, and diverse blockchain platforms. Additionally, the nanocarrier-based delivery system could be modified to accommodate different biomaterials and targeting mechanisms.

The present inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of personalized cancer treatment, supply chain management, and real-time monitoring of degradation. The target market includes pharmaceutical companies, hospitals, and research institutions.